Free Alerts   Login
Health Care › Pharmaceutical Preparations

AMRX Stock Price Correlated With Amneal Pharmaceuticals Financials

AMRX Stock Price vs. Quarterly
AMRX
Income Statement
Cash Flow
Balance Sheet

AMRX Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

AMRX Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

AMRX Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Fosun International
21,521,301 sh
 
$130,634
Vanguard Group
13,642,387 sh
94,087 sh
1%
$82,810
$25,636
TPG GP A
12,328,767 sh
 
$74,836
Blackrock.
8,846,421 sh
813,912 sh
10%
$53,698
$19,800
Rubric Capital Management Lp
8,000,000 sh
3,975,500 sh
99%
$48,560
$31,577
Citadel Advisors
6,497,090 sh
6,495,290 sh
360849%
$39,437
$39,429
Neuberger Berman Group
3,741,007 sh
-84,603 sh
-2%
$22,718
$6,539
Dimensional Fund Advisors
2,822,613 sh
847,801 sh
43%
$17,135
$8,800
State Street
2,799,057 sh
463,947 sh
20%
$16,990
$7,136
Geode Capital Management
2,439,247 sh
119,037 sh
5%
$14,808
$5,016
Nantahala Capital Management
2,334,397 sh
121,640 sh
5%
$14,170
$4,832
Nantahala Capital Management
2,334,397 sh
121,640 sh
5%
$14,170
$4,832
Nuveen Asset Management
1,958,207 sh
108,606 sh
6%
$11,886
$4,080
Invesco.
1,469,525 sh
1,051,649 sh
252%
$8,920
$7,157
Charles Schwab Investment Management
1,329,508 sh
26,875 sh
2%
$8,070
$2,573
Northernrp
1,320,635 sh
113,872 sh
9%
$8,017
$2,925
Lsv Asset Management
1,089,300 sh
-340,000 sh
-24%
$7
$1
Prudential Financial
1,028,326 sh
-254,100 sh
-20%
$6,242
$830
Aqr Capital Management
828,749 sh
-110,897 sh
-12%
$5,030
$1,065
Teacher Retirement System Of Texas
744,752 sh
24,651 sh
3%
$5
$2
COMPANY PROFILE
Nature of Operations Amneal Pharmaceuticals, Inc. (the “Company”) is a pharmaceutical company specializing in developing, manufacturing, marketing and distributing high-value generic and branded specialty pharmaceutical products across a broad array of dosage forms and therapeutic areas. The Company operates principally in the United States, India, and Ireland, and sells to wholesalers, distributors, hospitals, chain pharmacies and individual pharmacies, either directly or indirectly. The Company is a holding company, whose principal assets are common units (“Amneal Common Units”) of Amneal Pharmaceuticals, LLC (“Amneal”).

The group, together with their affiliates and certain assignees, who owned Amneal when it was a private company (the “Members” or the “Amneal Group”) held 50.4% of Amneal Common Units and the Company held the remaining 49.6% as of December 31, 2021.

In 2018, Amneal completed the acquisition of Impax Laboratories, Inc. (“Impax”), a generic and specialty pharmaceutical company.

Free historical financial statements for Amneal Pharmaceuticals Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 23 quarters since 2018. Compare with AMRX stock chart to see long term trends.

Data imported from Amneal Pharmaceuticals Inc SEC filings. Check original filings before making any investment decision.